Delcath Systems (NASDAQ:DCTH – Get Free Report) and STRATA Skin Sciences (NASDAQ:SSKN – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, valuation, earnings and risk.
Analyst Recommendations
This is a breakdown of current recommendations for Delcath Systems and STRATA Skin Sciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Delcath Systems | 0 | 0 | 4 | 0 | 3.00 |
| STRATA Skin Sciences | 0 | 0 | 0 | 0 | 0.00 |
Delcath Systems presently has a consensus target price of $21.50, indicating a potential upside of 128.97%. Given Delcath Systems’ stronger consensus rating and higher probable upside, research analysts plainly believe Delcath Systems is more favorable than STRATA Skin Sciences.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Delcath Systems | $2.07 million | 145.02 | -$47.68 million | ($1.35) | -6.96 |
| STRATA Skin Sciences | $33.36 million | 0.38 | -$10.83 million | ($2.66) | -1.13 |
STRATA Skin Sciences has higher revenue and earnings than Delcath Systems. Delcath Systems is trading at a lower price-to-earnings ratio than STRATA Skin Sciences, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Delcath Systems has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. Comparatively, STRATA Skin Sciences has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500.
Institutional and Insider Ownership
61.1% of Delcath Systems shares are owned by institutional investors. Comparatively, 32.4% of STRATA Skin Sciences shares are owned by institutional investors. 17.9% of Delcath Systems shares are owned by company insiders. Comparatively, 39.0% of STRATA Skin Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Delcath Systems and STRATA Skin Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Delcath Systems | -150.70% | -338.16% | -104.02% |
| STRATA Skin Sciences | -28.72% | -67.36% | -17.51% |
Summary
STRATA Skin Sciences beats Delcath Systems on 7 of the 13 factors compared between the two stocks.
About Delcath Systems
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
About STRATA Skin Sciences
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. The company products include XTRAC and Pharos excimer lasers, and VTRAC lamp systems for the treatment systems that are used for the treatment of psoriasis, vitiligo, and other skin conditions. It also offers TheraClear Acne Therapy System for the treatment of mild to moderate inflammatory, comedonal, and pustular acne. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.
